<DOC>
	<DOCNO>NCT02953938</DOCNO>
	<brief_summary>This Phase IV , randomize , open-label , active-controlled , 2-arm , multicenter study . The primary objective assess difference mean number ranibizumab injection apply Month 11 2 treatment arm . Patients randomize 1:1 ratio 1 2 treatment arm ; i.e . Arm 1 ranibizumab monotherapy , Arm 2 ranibizumab Grid &amp; Direct short pulse laser photocoagulation combination therapy . There 3 period study : Screening Period ( visit 1 ) , Treatment Period ( visit 2 Visit 13 ) Follow-up Period ( visit 14 ) . In addition screen Baseline ( visit 2 ) , monthly visit Month 1 Month 12 . This study include male female patient ( ≥20 year old ) diagnose visual impairment due ME secondary BRVO . Assuming approximate 20 % drop rate , approximately 70 patient need screen least 56 patient find eligible commence treatment trial .</brief_summary>
	<brief_title>Study Show Superior Benefit Terms Reduction Ranibizumab Injections Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss Efficacy Safety</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Diagnosis visual impairment exclusively due ME secondary BRVO Bestcorrected visual acuity score Screening Baseline ( Day 1 ) 0.5 0.05 decimal ( i.e. , 73 19 letter Early Treatment Diabetic Retinopathy Study ( ETDRS ) test ) Landolt C chart inclusively ( i.e. , approximate logarithm minimum angle resolution ( logMAR ) unit 0.3 1.30 ) . At Baseline ( Day1 ) , maximum BCVA gain 0.2 unit logMAR conversion inclusively screen allow long BCVA score exceed upper limit 0.3 unit logMAR . Increased central subfoveal thickness ( &gt; 300 µm Baseline ( Day 1 ) measure SDOCT ) Duration vision deterioration ≤6 month ( determine selfreport ) screening Pregnant nursing ( lactate ) woman Stroke myocardial infarction le 3 month Screening Uncontrolled blood pressure define systolic value &gt; 160 mm Hg diastolic value &gt; 100 mm Hg Screening Baseline ( Day 1 ) Antihypertensive treatment initiate must take least 30 day patient assess study eligibility second time Any active periocular ocular infection inflammation ( e.g. , blepharitis , conjunctivitis , keratitis , scleritis , uveitis , endophthalmitis ) time Screening Baseline ( Day 1 ) either eye Uncontrolled glaucoma ( intraocular pressure ( IOP ) ≥30 mm Hg medication accord investigator 's judgment ) time Screening Baseline ( Day 1 ) diagnose within 6 month Baseline ( Day 1 ) either eye Neovascularization iris neovascular glaucoma study eye Use systemic antiVEGF drug within 6 month Baseline ( Day1 ) ( e.g. , sorafenib ( Nexavar® ) , sunitinib ( Sutent® ) , bevacizumab ( Avastin® ) , zivaflibercept ( ZALTRAP® ) ) Treatment ( anticipate treatment fellow eye nonRVO indication study ) antiangiogenic drug ( include antiVEGF agent ) within 3 month Baseline ( Day1 ) fellow eye Baseline ( Day 1 ) study eye ( e.g. , pegaptanib ( Macugen® ) , ranibizumab ( Lucentis® ) , bevacizumab ( Avastin® ) , aflibercept ( EYLEA® ) ) Panretinal laser photocoagulation within 1 month Baseline ( Day1 ) anticipate schedule within next 12 month ( Study period ) follow Baseline ( Day1 ) study eye Any give focal grid laser photocoagulation Baseline ( Day1 ) study eye Use intra periocular corticosteroid ( include subTenon ) within 3 month Screening study eye . Any use intraocular corticosteroid implant ( e.g. , dexamethasone ( Ozurdex® ) , fluocinolone acetonide ( Iluvien® ) ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ranibizumab</keyword>
	<keyword>Grid &amp; Direct short pulse laser photocoagulation</keyword>
	<keyword>Macular edema ,</keyword>
	<keyword>Branch retinal vein occlusion ( BRVO )</keyword>
	<keyword>BCVA</keyword>
	<keyword>CSFT</keyword>
	<keyword>pro nata</keyword>
</DOC>